Derik De Bruin
Stock Analyst at B of A Securities
(4.46)
# 333
Out of 4,711 analysts
205
Total ratings
62.76%
Success rate
13.92%
Average return
Main Sectors:
Stocks Rated by Derik De Bruin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RVTY Revvity | Upgrades: Buy | $138 | $112.56 | +22.60% | 2 | Dec 13, 2024 | |
| TMO Thermo Fisher | Maintains: Buy | $675 → $660 | $524.05 | +25.94% | 18 | Dec 13, 2024 | |
| MYGN Myriad Genetics | Maintains: Underperform | $15 → $13 | $13.36 | -2.69% | 12 | Dec 13, 2024 | |
| IQV IQVIA Holdings | Maintains: Buy | $255 → $235 | $197.27 | +19.13% | 3 | Dec 13, 2024 | |
| EXAS Exact Sciences | Maintains: Buy | $75 → $72 | $59.40 | +21.21% | 6 | Dec 13, 2024 | |
| CRL Charles River Laboratories International | Maintains: Neutral | $220 → $210 | $185.77 | +13.04% | 5 | Dec 13, 2024 | |
| A Agilent Technologies | Maintains: Neutral | $153 → $150 | $134.51 | +11.52% | 31 | Dec 13, 2024 | |
| WAT Waters | Maintains: Neutral | $400 → $430 | $368.16 | +16.80% | 12 | Dec 13, 2024 | |
| WST West Pharmaceutical Services | Maintains: Buy | $350 → $355 | $331.40 | +7.12% | 7 | Dec 13, 2024 | |
| STVN Stevanato Group | Maintains: Buy | $24 → $26 | $20.56 | +26.46% | 4 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $19 | $16.41 | +15.78% | 4 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $262 → $271 | $228.61 | +18.54% | 8 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $179 → $182 | $153.10 | +18.88% | 5 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $78 → $80 | $57.00 | +40.35% | 12 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $290 | $228.55 | +26.89% | 4 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $13 → $15 | $21.69 | -30.84% | 4 | Aug 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $26 → $21 | $19.26 | +9.03% | 5 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $36 → $25 | $14.04 | +78.06% | 8 | Jul 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $38 → $32 | $19.44 | +64.61% | 1 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $140 → $100 | $136.02 | -26.48% | 11 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $94 → $86 | $71.65 | +20.03% | 11 | Aug 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $13 | $4.47 | +190.83% | 1 | Jun 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1,650 → $1,525 | $1,230.74 | +23.91% | 9 | May 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $9 → $6.5 | $2.31 | +181.39% | 1 | Jan 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $265 → $260 | $207.51 | +25.30% | 1 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $240 → $120 | $10.08 | +1,090.48% | 3 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $61 | $44.67 | +36.04% | 5 | Oct 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $111 → $120 | $164.84 | -27.20% | 2 | Jul 1, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $10 → $9 | $3.50 | +157.14% | 7 | May 8, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $275 → $235 | $412.26 | -43.00% | 3 | Nov 2, 2018 |
Revvity
Dec 13, 2024
Upgrades: Buy
Price Target: $138
Current: $112.56
Upside: +22.60%
Thermo Fisher
Dec 13, 2024
Maintains: Buy
Price Target: $675 → $660
Current: $524.05
Upside: +25.94%
Myriad Genetics
Dec 13, 2024
Maintains: Underperform
Price Target: $15 → $13
Current: $13.36
Upside: -2.69%
IQVIA Holdings
Dec 13, 2024
Maintains: Buy
Price Target: $255 → $235
Current: $197.27
Upside: +19.13%
Exact Sciences
Dec 13, 2024
Maintains: Buy
Price Target: $75 → $72
Current: $59.40
Upside: +21.21%
Charles River Laboratories International
Dec 13, 2024
Maintains: Neutral
Price Target: $220 → $210
Current: $185.77
Upside: +13.04%
Agilent Technologies
Dec 13, 2024
Maintains: Neutral
Price Target: $153 → $150
Current: $134.51
Upside: +11.52%
Waters
Dec 13, 2024
Maintains: Neutral
Price Target: $400 → $430
Current: $368.16
Upside: +16.80%
West Pharmaceutical Services
Dec 13, 2024
Maintains: Buy
Price Target: $350 → $355
Current: $331.40
Upside: +7.12%
Stevanato Group
Dec 13, 2024
Maintains: Buy
Price Target: $24 → $26
Current: $20.56
Upside: +26.46%
Dec 13, 2024
Maintains: Neutral
Price Target: $18 → $19
Current: $16.41
Upside: +15.78%
Dec 13, 2024
Maintains: Buy
Price Target: $262 → $271
Current: $228.61
Upside: +18.54%
Dec 13, 2024
Maintains: Buy
Price Target: $179 → $182
Current: $153.10
Upside: +18.88%
Dec 13, 2024
Maintains: Buy
Price Target: $78 → $80
Current: $57.00
Upside: +40.35%
Dec 13, 2024
Upgrades: Buy
Price Target: $290
Current: $228.55
Upside: +26.89%
Aug 30, 2024
Maintains: Underperform
Price Target: $13 → $15
Current: $21.69
Upside: -30.84%
Aug 13, 2024
Maintains: Underperform
Price Target: $26 → $21
Current: $19.26
Upside: +9.03%
Jul 18, 2024
Maintains: Neutral
Price Target: $36 → $25
Current: $14.04
Upside: +78.06%
Feb 29, 2024
Maintains: Neutral
Price Target: $38 → $32
Current: $19.44
Upside: +64.61%
Dec 12, 2023
Downgrades: Underperform
Price Target: $140 → $100
Current: $136.02
Upside: -26.48%
Aug 1, 2023
Maintains: Neutral
Price Target: $94 → $86
Current: $71.65
Upside: +20.03%
Jun 16, 2023
Downgrades: Neutral
Price Target: $13
Current: $4.47
Upside: +190.83%
May 8, 2023
Maintains: Neutral
Price Target: $1,650 → $1,525
Current: $1,230.74
Upside: +23.91%
Jan 4, 2023
Downgrades: Underperform
Price Target: $9 → $6.5
Current: $2.31
Upside: +181.39%
Nov 9, 2022
Upgrades: Buy
Price Target: $265 → $260
Current: $207.51
Upside: +25.30%
May 18, 2022
Downgrades: Underperform
Price Target: $240 → $120
Current: $10.08
Upside: +1,090.48%
Oct 6, 2020
Upgrades: Buy
Price Target: $61
Current: $44.67
Upside: +36.04%
Jul 1, 2019
Downgrades: Neutral
Price Target: $111 → $120
Current: $164.84
Upside: -27.20%
May 8, 2019
Reiterates: Underperform
Price Target: $10 → $9
Current: $3.50
Upside: +157.14%
Nov 2, 2018
Maintains: Buy
Price Target: $275 → $235
Current: $412.26
Upside: -43.00%